Evidence map›Paper›PMID 41424720›Full record

ArticlePeerJ2025

Simpler predictive models provide higher accuracy for ovarian cancer detection.

Derrick E Wood, Joseph Roy, Bari J Ballew

Abstract read
In one paragraph

Article in PeerJ, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Derrick E WoodBlackjack Biotechnologies, Baltimore, MD, United States of America.
Joseph RoyBlackjack Biotechnologies, Baltimore, MD, United States of America.
Bari J BallewBlackjack Biotechnologies, Baltimore, MD, United States of America.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ovarian cancer remains a danger to women's health, and accurate screening tests would likely increase survival. Two established protein biomarkers, CA125 and HE4, have been shown to work well in isolation, but achieve even higher accuracy when combined using logistic regression (LR). This LR-based combination of protein concentrations achieves high accuracy when distinguishing healthy samples from cancer samples (area under the curve (AUC) = 0.99). The dataset we use was obtained from a previous publication that described DELFI-Pro, an LR model combining features derived from cell-free DNA (cfDNA) with the two proteins' concentrations. We show that many of DELFI-Pro's cfDNA features are affected by confounding technical variation within training data, which impacts the previously reported results. A minority of the training data's cancer samples (42 of 94) have chromosomal copy number values that are markedly different from the other samples used to evaluate the DELFI-Pro screening model. After removing those 42 samples from the training data, we find that DELFI-Pro does not outperform CA125 or CA125+HE4 protein-only screening classifiers even in cross validation, including a two-protein model published alongside the DELFI-Pro model. We conclude that DELFI-Pro does not adequately justify the inclusion of its cfDNA features. Our results are in line with the principle that simpler machine learning models will tend to exhibit better generalizability on new data.

Indexed as

Biomarkers, TumorEarly Detection of CancerOvarian NeoplasmsCA-125 AntigenCell-Free Nucleic AcidsFemaleHumansLogistic ModelsMembrane ProteinsWAP Four-Disulfide Core Domain Protein 2Biomarkers, TumorCA-125 AntigenCell-Free Nucleic AcidsMembrane ProteinsMUC16 protein, humanWAP Four-Disulfide Core Domain Protein 2WFDC2 protein, humanCancer detectionCancer diagnosticsCancer screeningMachine learningOvarian cancer

Identifiers

PMID41424720
PMCPMC12716435

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.